• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吲哚胺 2,3-双加氧酶（IDO）表达在接受伊匹木单抗治疗的转移性黑色素瘤中的预后及预测价值

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.

作者信息

von Bubnoff Dagmar, Schmitt Christina, Goldinger Simone M, Schadendorf Dirk, Kähler Katharina C, Hafner Christian, Kramer Nora, Fröhlich Waltraud, Dummer Reinhard, Berking Carola, Schliep Stefan, Kirchberger Michael C, Heinzerling Lucie

机构信息

Department of Dermatology, University Hospital Lübeck, Lübeck, Germany.

Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.

出版信息

PLoS One. 2025 May 7;20(5):e0321937. doi: 10.1371/journal.pone.0321937. eCollection 2025.

DOI:10.1371/journal.pone.0321937
PMID:40334245
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12058187/
Abstract

BACKGROUND

The tumor microenvironment is crucial for prognosis and response to immunotherapy in several tumor entities.

METHODS

In a multicenter retrospective study, a total of 86 tumor samples from patients with metastatic melanoma were evaluated for baseline expression of indoleamine 2,3-dioxygenase (IDO) and programmed death ligand 1 (PD-L1). Expression patterns of IDO and PD-L1 on tumor cells and antigen-presenting cells (APCs) as determined by immunohistochemical (IHC) staining of paraffin-embedded tissue sections were correlated with response to ipilimumab and overall survival (OS). Statistical analysis was performed using the Spearman correlation, the Mann-Whitney test and Kaplan-Meier estimator.

RESULTS

IDO expression in tumor cells or APCs was not predictive for treatment response. The median OS was 26 months in IDO-positive and IDO-negative patients, regardless of IDO expression in tumor cells or APCs. A correlation of IHC expression scores of IDO and PD-L1 could not be documented.

CONCLUSION

The exact role of IDO in creating an immunosuppressive tumor environment and its reversal needs to be further elucidated.

摘要

背景

肿瘤微环境对多种肿瘤实体的预后及免疫治疗反应至关重要。

方法

在一项多中心回顾性研究中，对86例转移性黑色素瘤患者的肿瘤样本进行评估，检测吲哚胺2,3-双加氧酶（IDO）和程序性死亡配体1（PD-L1）的基线表达。通过对石蜡包埋组织切片进行免疫组织化学（IHC）染色，确定IDO和PD-L1在肿瘤细胞及抗原呈递细胞（APC）上的表达模式，并将其与伊匹单抗治疗反应及总生存期（OS）相关联。采用Spearman相关性分析、Mann-Whitney检验及Kaplan-Meier估计法进行统计分析。

结果

肿瘤细胞或APC中IDO的表达不能预测治疗反应。无论肿瘤细胞或APC中IDO的表达情况如何，IDO阳性和IDO阴性患者的中位OS均为26个月。未发现IDO和PD-L1的IHC表达评分之间存在相关性。

结论

IDO在创建免疫抑制性肿瘤环境中的确切作用及其逆转机制有待进一步阐明。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/ea4aaf792b9c/pone.0321937.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/e3b81eb41f24/pone.0321937.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/08fbd1478b8c/pone.0321937.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/70b651210dfe/pone.0321937.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/88bfbe66097c/pone.0321937.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/a59e7582bd21/pone.0321937.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/76ab7c1f57e3/pone.0321937.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/ea4aaf792b9c/pone.0321937.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/e3b81eb41f24/pone.0321937.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/08fbd1478b8c/pone.0321937.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/70b651210dfe/pone.0321937.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/88bfbe66097c/pone.0321937.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/a59e7582bd21/pone.0321937.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/76ab7c1f57e3/pone.0321937.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d2/12058187/ea4aaf792b9c/pone.0321937.g007.jpg

相似文献

1
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.吲哚胺 2,3-双加氧酶（IDO）表达在接受伊匹木单抗治疗的转移性黑色素瘤中的预后及预测价值
PLoS One. 2025 May 7;20(5):e0321937. doi: 10.1371/journal.pone.0321937. eCollection 2025.
2
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments.黑色素瘤脑转移患者的真实世界转归：一项关于全身治疗的美国多中心回顾性病历审查研究
BMJ Open. 2025 Jan 30;15(1):e091098. doi: 10.1136/bmjopen-2024-091098.
3
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.肢端雀斑样痣黑色素瘤国际患者队列中程序性细胞死亡蛋白1与细胞毒性T淋巴细胞相关蛋白4联合阻断治疗
Br J Dermatol. 2025 Jan 24;192(2):316-326. doi: 10.1093/bjd/ljae401.
4
Neoadjuvant treatment for stage III and IV cutaneous melanoma.新辅助治疗 III 期和 IV 期皮肤黑色素瘤。
Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
The prognostic value of halp score in predicting the efficacy of nivolumab treatment in metastatic malignant melanoma patients: A real-life, retrospective, single center analysis.HALP评分在预测转移性恶性黑色素瘤患者纳武利尤单抗治疗疗效中的预后价值：一项真实世界、回顾性、单中心分析。
Medicine (Baltimore). 2025 May 2;104(18):e42261. doi: 10.1097/MD.0000000000042261.
7
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.吲哚胺 2,3-双加氧酶（IDO）抑制剂与癌症免疫治疗。
Cancer Treat Rev. 2022 Nov;110:102461. doi: 10.1016/j.ctrv.2022.102461. Epub 2022 Aug 30.
8
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.晚期 NSCLC 中 PD-L1 的表达：系统文献回顾对风险分层和治疗选择的启示。
Lung Cancer. 2017 Oct;112:200-215. doi: 10.1016/j.lungcan.2017.08.005. Epub 2017 Aug 10.
9
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.在免疫治疗时代，探索肛管鳞状细胞癌免疫细胞预测生物标志物和可操作基因改变中的程序性死亡受体配体1（PD-L1）
ESMO Open. 2025 Jun;10(6):105315. doi: 10.1016/j.esmoop.2025.105315. Epub 2025 Jun 10.
10
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.一线纳武利尤单抗联合基于伊匹木单抗的治疗方案用于肿瘤程序性死亡配体1低于1%的转移性非小细胞肺癌患者的长期生存结果：一项汇总分析
J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4.

引用本文的文献

1
The prognostic value of indoleamine 2,3-dioxygenase in colorectal cancer: a systematic review and meta-analysis.吲哚胺2,3-双加氧酶在结直肠癌中的预后价值：一项系统评价和荟萃分析。
BMC Gastroenterol. 2025 Aug 20;25(1):603. doi: 10.1186/s12876-025-04124-2.
2
Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology.微环境与肿瘤异质性作为精准肿瘤学中的药理学靶点
Pharmaceuticals (Basel). 2025 Jun 18;18(6):915. doi: 10.3390/ph18060915.

本文引用的文献

1
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.不同组织类型肿瘤 PD-L1 表达与基于 PD-1 的免疫治疗转移性黑色素瘤疗效的相关性——DeCOG 前瞻性多中心队列研究 ADOREG/TRIM 分析。
EBioMedicine. 2023 Oct;96:104774. doi: 10.1016/j.ebiom.2023.104774. Epub 2023 Sep 4.
2
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.用于检测非小细胞肺癌中PD-L1及预测帕博利珠单抗反应的E1L3N抗体的验证
Commun Med (Lond). 2022 Nov 1;2(1):137. doi: 10.1038/s43856-022-00206-4.
3
PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
PD-L1 表达在三阴性乳腺癌中的研究——三种不同抗体的比较。
Appl Immunohistochem Mol Morphol. 2022;30(10):726-730. doi: 10.1097/PAI.0000000000001062. Epub 2022 Sep 21.
4
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.吲哚胺 2,3-双加氧酶（IDO）抑制剂与癌症免疫治疗。
Cancer Treat Rev. 2022 Nov;110:102461. doi: 10.1016/j.ctrv.2022.102461. Epub 2022 Aug 30.
5
Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.肿瘤类型的免疫分类与精准联合免疫治疗进展
Front Immunol. 2022 Feb 28;13:790113. doi: 10.3389/fimmu.2022.790113. eCollection 2022.
6
Cross-reactivity between microbial and tumor antigens.微生物抗原与肿瘤抗原的交叉反应性。
Curr Opin Immunol. 2022 Apr;75:102171. doi: 10.1016/j.coi.2022.102171. Epub 2022 Feb 24.
7
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
8
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.纳武利尤单抗联合伊匹单抗或纳武利尤单抗对比伊匹单抗治疗晚期黑色素瘤患者的长期结局。
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
9
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.IDO 通路抑制剂吲哚美辛联合派姆单抗治疗晚期黑色素瘤的 II 期临床试验。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002057.
10
The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.FoxP3+ 调节性 T 细胞和 IDO+ 免疫和肿瘤细胞在恶性黑色素瘤中的作用——免疫组化研究。
BMC Cancer. 2021 May 29;21(1):641. doi: 10.1186/s12885-021-08385-4.